SCOTTISH biotech company Ryboquin has acquired its partner Nanogenic Solutions in a £4.5 million deal which it says will help to “revolutionise” gene therapy.
Ryboquin, spun out of Edinburgh-based medicine developer Ectopharma in 2013, will form a new company called Nanogenics as it develops its artificial virus LipTide, which acts as a custom-built delivery system that can be modified to target different cell types.
The company, based in Selkirk in the Borders, is focused on commercialising patented intellectual property in the area of delivering gene therapy, primarily to cancer patients. LipTide is a protein-based nanoparticle which mimics natural viruses but bypasses the many problems of viral delivery.
Dr Alan Walker, chief executive of Nanogenics, said: “It will offer real hope to those millions of patients living with diseases who have been unable to benefit from the advances in gene therapy because, until now, it has been so difficult to safely deliver the correct gene therapy to the right target.
“That can now change and we are already working with six major biotech companies who want to access this exciting delivery mechanism.”
As well as working with partners to deliver their gene therapy programmes, Nanogenics is developing its own product pipeline, taking advantage of the LipTide delivery platform. LipTide-ECP102, on which Nanogenics has US and EU patents, is said to dramatically enhance chemotherapy and radiotherapy.
The firm confirmed that a clinical trial is planned at the Christie Hospital Manchester in 2020. LipTide-ECP102 is currently being scaled up to an industrial batch in collaboration with Strathclyde University.
Nanogenics’ executive chairman, Paul Murray, said that considerable effort had gone into convincing investors of the “huge potential” of LipTide. “We plan to grow the company quickly to a stage where we can take it public as soon as that is feasible,” he said. “It is very rewarding to be involved in the cutting edge of medical science.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article